Press coverage about Biostar Pharmaceuticals (NASDAQ:BSPM) has trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biostar Pharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.0944694758021 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Biostar Pharmaceuticals traded down $0.03, hitting $2.73, during midday trading on Thursday, Marketbeat reports. 1,823 shares of the stock traded hands, compared to its average volume of 308,683. The company has a market cap of $7.36 million, a price-to-earnings ratio of 3.99 and a beta of 2.30. Biostar Pharmaceuticals has a one year low of $2.66 and a one year high of $2.73.
About Biostar Pharmaceuticals
Biostar Pharmaceuticals, Inc develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B.
Receive News & Ratings for Biostar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.